You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨艾美疫苗升約9.8% mRNA帶狀皰疹疫苗國內獲批開展臨牀
格隆匯 05-19 10:32
艾美疫苗(6660.HK)升約9.8%,報3.59港元。消息面上,艾美疫苗發佈公吿,繼2025年3月該疫苗獲美國食品和藥品監督管理局(FDA)批准開展臨牀試驗後,集團研發的mRNA帶狀皰疹疫苗已於近日獲得國家藥品監督管理局《藥物臨牀試驗批准通知書》。臨牀前試驗中,第三方檢測單位的檢測結果顯示,集團mRNA帶狀皰疹疫苗特異性T細胞免疫、特異性IgG抗體滴度、膜抗原螢光抗體(FAMA)滴度,均顯著高於國際市售重組亞單位對照疫苗。(格隆匯)
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account